ATTBF - Abattis Bioceuticals Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0690
0.0000 (0.00%)
As of 11:28AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0690
Open0.0740
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.0654 - 0.0760
52 Week Range0.0420 - 0.7444
Volume328,209
Avg. Volume1,014,133
Market Cap29.35M
Beta (3Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.078
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile3 days ago

    Abattis Bioceuticals Corp., A Fully Integrated Medical Marijuana Company, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - December 14, 2018) - CEO & President of Abattis Bioceuticals Corp., Robert Abenante, speaks on the medical marijuana company's many facets including: a vape line, extraction and laboratory services.If you cannot view the video above, please visit:https://www.b-tv.com/abattis-bioceuticals-ceo-clip-90sec/Abattis Bioceuticals Corp. is being featured on BNN Bloomberg on Dec. 15 - Dec. 16, 2018, throughout the day and evenings.Abattis Bioceuticals (CSE: ATT) (OCTQB: ATTBF)abattis.comAbout CEO Clips:CEO Clips is the largest library ...

  • GlobeNewswire6 days ago

    Comfort Launch by Vergence Naturals Exceeds Expectations

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide an update on the recent soft-launch of its cannabinoid-infused nutraceutical Comfort (“Comfort”) through the Company’s wholly-owned subsidiary, Vergence Naturals (“Vergence”), on Cyber-Monday, November 26, 2018. Canada One Communications Inc. (“Canada One”), an Abattis media partner, quotes WorkArea.com in selecting Monday as the best day for e-commerce site sales.

  • GlobeNewswire7 days ago

    Abattis to Display Products and Services at O’Cannabiz Conference on December 10-11th, 2018

    Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that the Company will be displaying a booth at the O’Cannabiz Conference and Expo taking place at Parq Casino in Vancouver, BC on December 10-11th, 2018 (“O’Cannabiz”). O’Cannabiz will address key cannabis investment themes, emerging opportunities in the developing Canadian market, as well as significant trends and developments in the cannabis industry, from consumers to businesses. The conference will display over 100 global and local cannabis professionals, offering attendees and investors up to date information on what’s next for Canada’s growing cannabis industry.

  • GlobeNewswire10 days ago

    Abattis Announces Acquisition of Fertilizer Company NutriVida

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has signed a non-binding letter of intent dated December 6, 2018 (the “LOI”)  to acquire 100% interest in NutriVida Corp. (“NutriVida”) through an arm’s length transaction, a privately held fertilizer and nutrient company located in Langley, BC. The acquisition of Nurtivida plays directly into the Company’s push to add to its current and future cannabis growth assets, including, but not limited to, its acquisition of Gabriola Green Farms Inc. earlier in 2018. Specifically, the management of NutriVida has been a prominent force in the fertilizer and cultivation industry, with over 35 years of experience and, providing a vast wealth of knowledge and experience in researching, innovating, manufacturing, and selling all-natural, bio-safe, fertilizers and plant nutrients.

  • GlobeNewswire20 days ago

    Abattis Comments on BCSC Temporary Order

    Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) comments on the news release regarding the British Columbia Securities Commission (“BCSC”) Temporary Order dated November 26, 2018. The BCSC issued a temporary order on Monday, November 26, 2018, which centers around share issuances by 11 CSE issuers to a very large group of consultants between February, 2018, and August, 2018.  Abattis has been named as 1 of the 11 issuers as they have ongoing consulting agreements with certain members listed in the group of respondents (the “Respondents”) for services ranging from accounting and finance to marketing.  Also, certain of the Respondents participated in an Abattis private placement for $2.25M.  For these reasons, Abattis has been named as an issuer in this temporary order.

  • PR Newswire20 days ago

    Abattis Bioceuticals Signs National Distribution Agreement With Shefield & Sons

    Abattis Bioceuticals Corp (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that the Company has signed a Distribution Agreement (the "Distribution Agreement") with Shefield & Sons Tobacconists Inc. ("Shefield & Sons") to sell the Abattis vaporizer line in all Shefield & Sons stores across Canada. Shefield & Sons has been in business since 1976 and is one of Canada's pre-eminent tobacconist franchisors with locations in major cities across Canada.

  • CNW Group20 days ago

    Abattis Bioceuticals Signs National Distribution Agreement With Shefield & Sons

    VANCOUVER , Nov. 27, 2018 /CNW/ - Abattis Bioceuticals Corp (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that the Company has signed a Distribution Agreement (the "Distribution Agreement") with Shefield & Sons Tobacconists Inc. ("Shefield & Sons") to sell the Abattis vaporizer line in all Shefield & Sons stores across Canada . Shefield & Sons has been in business since 1976 and is one of Canada's pre-eminent tobacconist franchisors with locations in major cities across Canada .

  • GlobeNewswire21 days ago

    Abattis Bioceuticals Celebrates Release of Comfort Through Vergence Naturals

    Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce the release of its first proprietary product, Comfort, through the Company’s wholly-owned subsidiary Vergence Naturals (“Vergence”). Comfort, a brand-new proprietary nutraceutical, which contains Alpinia Galangal and Capsicum Annuum, was developed by Abattis’ research scientists to activate the endocannabinoid system (“ECS”) and nourish endorphin release in response to pain. Comfort Extra Strength, the second addition to the Comfort product line, is set to be released to the public in mid-January 2019 and will be enhanced with hemp-based phytocannabinoids, with a specific focus on cannabidiol (CBD).

  • GlobeNewswire24 days ago

    Abattis Bioceuticals Acquires Proprietary Genetic Strain Bank

    Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) to acquire 100% of Select Strains Inc. (“Select Strains”). Select Strains has almost two decades of experience within the cannabis space, specifically within the fields of cannabis testing, research, cultivation and optimization of proprietary seeds and strains. With a portfolio of over 140 laboratory-tested craft cannabis strains, Select Strains will allow for the continued differentiation of the Abattis brand, leveraging unique craft strains in an increasingly generic, highly competitive and standardised cannabis market.

  • GlobeNewswire26 days ago

    Abattis Retains Canadian and American Compliance Agency and Provides Company Update

    Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce the appointment of Ingredient Identity LLC (“Ingredient Identity”), a Canadian and US regulatory and compliance agency, to assist the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. (“Vergence Naturals”), with their ongoing Canadian and US regulatory compliance program. “Regulatory compliance is a cornerstone objective for Vergence Naturals, or any nutraceutical business,” stated Rob Abenante, President and CEO of Vergence Naturals.

  • GlobeNewswire2 months ago

    Abattis Bioceuticals Offers Comfort to Those Suffering with Chronic Pain & Inflammation -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering the launch of Abattis Bioceuticals Corp.'s (ATT.CN) (ATTBF) latest product innovation. “Comfort”, a nutraceutical designed to alleviate chronic pain and inflammation, is the first in line of a dozen new products the company expects to launch over 36 months. According to a recent Institute of Medicine Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, stated, “Acute or chronic pain is a significant public health problem that costs society at least $560-$635 billion annually in North America alone.

  • Newsfile2 months ago

    Abattis Bioceuticals Announces Board Change

    Vancouver, British Columbia--(Newsfile Corp. - October 19, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") is pleased to announce the additions of Kent McParland and Cedric Wilson to the Board of Directors (the "Board"). Mr. McParland and Mr. Wilson replace Cameron Paddock and Rene David who have left Abattis to concentrate on other ventures. Mr. McParland is a Chartered Professional Accountant experienced in multiple industries and geographical locations. ...

  • GlobeNewswire2 months ago

    Abattis Bioceuticals Celebrates Legalization

    Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to celebrate the legalization of cannabis in Canada. This is a truly a newsworthy day in Canadian history, as we formally recognize the end of cannabis prohibition in our country. As Ottawa subsequently, decreed Legalization on Oct.17th, 2018 - Canada is now the second country in the world, and first G7 nation to legalize marijuana production, sale and consumption country-wide.

  • GlobeNewswire2 months ago

    Abattis Bioceuticals Provides Update on Vaporizer Product Line

    Abattis Bioceuticals Corp. (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce an update on our recent product line addition of three new vaporizers. The “VB-2” uses a compact 350mAh variable voltage battery, designed with built-in protections against short-circuiting and overheating, and features a conventional preheating function that the user activates with two clicks of a button. The cutting-edge device is equipped with a 510-threaded connection that can be closed to house attachments and features a built-in USB charging cable, a long-lasting embedded 350mAh lithium ion battery, a key ring and an LED light indicator.

  • GlobeNewswire3 months ago

    Abattis Unveils “Comfort”, Its Proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the Company hopes to launch Comfort on Cyber Monday through the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. “According to a report from the Industry of Medicine, more than 100 million people in North America suffer from chronic pain and inflammation1,” stated Rob Abenante, Abattis President and CEO.  “That same report estimates the pain-price tag for medical treatments and lost productivity at more than $600 billion annually1, making chronic pain and inflammation major drains on the economy.